Immunodiagnostics and Vaccine Development at Viravaxx AG Gain Momentum

By: Viravaxx
VIENNA - Jan. 13, 2021 - PRLog -- Fast-track development of vaccines against COVID-19 and other infectious diseases are facilitated by microarray-based assays for whole-proteome analysis and vaccine design platforms. Both have been developed by Viravaxx AG, and the company's recent progress with its SARS-CoV-2 Interaction Assay offered a turning point.

Concomitantly, as of Jan 1, 2021, Viravaxx has recruited Dr. Helmut Brunar as its new CEO. Dr. Brunar brings vast expertise in vaccines, cell-therapies and diagnostic products to the company. Before joining Viravaxx, he managed supply chain activities at Johnson & Johnson's COVID-19 vaccine program. Prior to this, he was CEO & Chairman with Axentis Pharma AG where he built a team to develop respiratory drug candidate AX-TOBRA. Dr. Brunar will take over from Dr. Rainer Henning, who has made invaluable contributions for establishing the company at the forefront of innovative immunodiagnostics and vaccine development.

The management team is completed with Dr. Frank Stolz, who has been with Viravaxx since its inception. Dr. Stolz is an experienced head of pre-clinical and clinical product development with a successful history of working in biotechnology and in basic research. At Viravaxx, he is responsible for product innovation, process and analytical development. He leads Viravaxx's preclinical vaccine development and diagnostic platforms.

Viravaxx AG

Dr. Helmut Brunar, CEO

Mariannengasse 14/9

1090 Vienna, Austria

T +43 1 7966 296 100

Email:*** Email Verified
Location:Vienna - Vienna - Austria
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
PR&D - Public Releations for Research & Education News
Most Viewed
Daily News

Like PRLog?
Click to Share